← Leaderboards
Laura E Benjamin
Beth Israel Deaconess Medical Center
$10,185,711
Attributed
$10,651,908
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–13$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$10,651,908 · 8
By mechanism
R01$9,212,941 · 6
P01$1,438,967 · 2
Top collaborators
- Harold Fisher Dvorak2 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Harold Fisher Dvorak$13,877,917
- Huiyan Zeng$2,837,132
- Donald R Senger$6,635,477
- Janice Nagy$425,000
Others in their field
Top investigators on “Angiogenesis”
- David Heimbrook · Leidos Biomedical Research, Inc.$75,067,502
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,567,306
- Martin Friedlander · Scripps Research Institute$48,350,175
- Larry Arthur$33,866,306
- Michael Simons · Yale University$30,647,106
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$29,372,588
Research focus
AngiogenesisBlood VesselsSignal PathwayPathway InteractionsInvestigationTumorSignal TransductionMediatingNeoplasm MetastasisRegulationProteinsMolecularResponseIn VivoNeoplastic CellEndothelial CellsCellsTissuesTraffickingMalignant NeoplasmsEndotheliumMammary GlandLymphaticSirolimus
Grant awards (29)
Akt Signaling Pathways in VEGF-A-induced Angiogenesis$283,147
P01 · FY2013 · CA · contact PI
Akt Signaling Pathways in VEGF-A-induced Angiogenesis$292,351
P01 · FY2012 · CA · contact PI
Akt Signaling Pathways in VEGF-A-induced Angiogenesis$305,080
P01 · FY2011 · CA · contact PI
VEGFs in tumor lymphatic metastasis$473,057
R01 · FY2010 · CA · contact PI
Downstream of Akt in the tumor vessel$469,176
R01 · FY2010 · CA · contact PI
Microvascular Remodeling in Development$425,000
R01 · FY2010 · HL · contact PI
Akt Signaling Pathways in VEGF-A-induced Angiogenesis$248,082
P01 · FY2010 · CA · contact PI
Downstream of Akt in the tumor vessel$459,978
R01 · FY2009 · CA · contact PI
VEGFs in tumor lymphatic metastasis$459,337
R01 · FY2009 · CA · contact PI
Microvascular Remodeling in Development$425,000
R01 · FY2009 · HL · contact PI
AKT pathway as a therapeutic tumor vessel target$402,342
R01 · FY2009 · CA · contact PI
Angiogenesis in Breast Cancer$318,352
R01 · FY2009 · CA · contact PI
Akt Signaling Pathways in VEGF-A-induced Angiogenesis$310,307
P01 · FY2009 · CA · contact PI
Downstream of Akt in the tumor vessel$446,580
R01 · FY2008 · CA · contact PI
Microvascular Remodeling in Development$425,000
R01 · FY2008 · HL · contact PI
AKT pathway as a therapeutic tumor vessel target$389,596
R01 · FY2008 · CA · contact PI
Survival Signaling in Breast Cancer$330,443
R01 · FY2008 · CA · contact PI
Angiogenesis in Breast Cancer$318,352
R01 · FY2008 · CA · contact PI
Survival Signaling in Breast Cancer$330,443
R01 · FY2007 · CA · contact PI
Angiogenesis in Breast Cancer$318,352
R01 · FY2007 · CA · contact PI
Microvascular remodeling in development$373,512
R01 · FY2006 · HL · contact PI
Survival Signaling in Breast Cancer$340,311
R01 · FY2006 · CA · contact PI
Angiogenesis in Breast Cancer$327,860
R01 · FY2006 · CA · contact PI
Microvascular remodeling in development$382,500
R01 · FY2005 · HL
Survival Signaling in Breast Cancer$348,500
R01 · FY2005 · CA
Angiogenesis in Breast Cancer$335,750
R01 · FY2005 · CA
Microvascular remodeling in development$382,500
R01 · FY2004 · HL
Survival Signaling in Breast Cancer$348,500
R01 · FY2004 · CA
Microvascular remodeling in development$382,500
R01 · FY2003 · HL